drugset / Trial / NCT00651378

Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)

NCT00651378

Phase 4 Terminated 87 enrolled Organon and Co Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study assesses whether adding ezetimibe 10 mg/d to ongoing treatment with atorvastatin 10 mg/d is more effective than switching the subject to treatment with rosuvastatin 10 mg/d or doubling the dose of atorvastatin to 20 mg/d is more effective in achieving goal LDL-cholesterol of \<2.5 mmol/L. Treatment phase is 6 weeks.

Timeline

Start
2004-09-01
Primary completion
2005-06-01
Completion
2005-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 10 mg Oral
Comparator Atorvastatin Small molecule 20 mg Oral
Comparator Ezetimibe Unknown 10 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral